Selected Publications:
Chawla S, Wang S, Mohan S, Nasrallah M, Verma G, Brem S, O'Rourke DM, Wolf RL, Poptani H, Nabavizadeh SA.: Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI J Magn Reson Imaging : 2018.
Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O'Rourke DM, Davatzikos C: Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics offering prognostic value beyond IDH1 Sci Reports 8 (1): 5087,2018.
Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O'Rourke DM, Davatzikos C: In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro Oncol : 2018.
Wang Q, He Z, Huang M, Liu Y, Wang Y, Xu H, Duan H, Ma P, Zhang L, Zamvil SS, Hidalgo J, Zhang Z, O'Rourke DM, Dahmane N, Brem S, Mou Y, Gong Y, Fan Y: Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2a Nat Communications 9 (1): 559,2018.
Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson C, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Orellana L, Scott AM, Davatzikos C, Furnari FB, O'Rourke DM.: Epidermal Growth Factor Receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development. Cancer Cell : 2018.
Morris J, NA YJ, Zhu H, Lee JH, Giang H, Ulyanova AV, Baltuch GH, Brem S, Chen HI, Kung DK, Lucas TH, O'Rourke DM, Wolf JA, Grady MS, Sul JY, Kim J, Eberwine J.: Pervasive within-Mitochondrion Single-Nucleotide Variant Heteroplasmy as Revealed by Single-Mitochondrion Sequencing. Cell Reports 21 (10): 2706-2713,2017.
Roccograndi L, Binder ZA, Zhang L, Aceta N, Zhang Z, Bentores-Alj M, Nakano, I, Dahmane N, O’Rourke DM.: Shp2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol 135 (3): 487-496,2017.
Weller M, Butowski N, Tran DD, Recht L, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust S, Iwamoto F, Drappatz J, O’Rourke DM, et al.: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): results of a randomized, double-blind, international phase 3 trial. Lancet Oncol. 18 (10): 1373-1385,2017.
Bakas S, Akbari H, Pisapia J, Martinez-Lage M, Rozycki M, Rathore S, Dahmane N, O'Rourke DM, Davatzikos C.: In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the φ index. Clin Cancer Res. 23 (16): 4724-4734,2017.
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma Science Translational Medicine 9 (399): pii.eaaa0984,2017.